CD19-targeting CAR T cells have gained significant attention, showing long-term, durable efficacy in patients with poly-refractory lymphomas, which traditionally have a very poor prognosis (Crump et al., 2017), and three CD19-targeting CAR T-cell products are currently approved for DLBCL and FL patients. Here, CD19 is linked to lymphoma.